文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

不明原因血细胞减少中体细胞突变的临床意义

Clinical significance of somatic mutation in unexplained blood cytopenia.
PubMed 文献 · Blood · 2017-04-19

该前瞻性队列研究纳入683例不明原因血细胞减少患者作为学习队列,另用190例疑似髓系肿瘤患者作为验证队列,检测40个髓系肿瘤相关基因的体细胞突变。携带变异等位基因频率≥0.10的突变或≥2个突变对诊断髓系肿瘤的阳性预测值分别为0.86和0.88;在诊断不明确者中,携带≥1个突变与随访期间发生髓系肿瘤的高概率相关(HR=13.9,P<.001),验证队列证实了突变的预测价值。

要点

  • 在不明原因血细胞减少患者中,435/683例携带至少1个髓系肿瘤相关基因的体细胞突变。
  • 变异等位基因频率≥0.10的突变诊断髓系肿瘤的阳性预测值为0.86,≥2个突变为0.88。
  • 诊断不明确者携带≥1个突变与随访期间发生髓系肿瘤的高概率相关(HR=13.9,P<.001)。

核心结论

  • 外周血粒细胞突变分析可能显著改善当前对不明原因血细胞减少的诊断方法,并更广泛地提高髓系肿瘤的诊断准确性。

研究设计与样本

  • 前瞻性队列研究,学习队列为683例连续纳入的不明原因血细胞减少患者,验证队列为190例疑似髓系肿瘤患者。
  • 使用粒细胞DNA检测40个在髓系恶性肿瘤中反复突变的基因的体细胞突变。

主要发现

  • 435/683例患者携带至少1个上述基因的体细胞突变。
  • 携带变异等位基因频率≥0.10的体细胞突变对诊断髓系肿瘤的阳性预测值为0.86。
  • 携带2个或以上突变对诊断髓系肿瘤的阳性预测值为0.88。
  • 涉及TET2、DNMT3A或ASXL1的剪接体基因突变和共突变模式对髓系肿瘤的阳性预测值为0.86至1.0。
  • 在诊断结果不明确的受试者中,携带1个或以上体细胞突变与随访期间发生髓系肿瘤的高概率相关(风险比=13.9,P<.001)。

关键数值与推荐

  • 携带变异等位基因频率≥0.10的体细胞突变对诊断髓系肿瘤的阳性预测值为0.86。
  • 携带2个或以上突变对诊断髓系肿瘤的阳性预测值为0.88。
  • 涉及TET2、DNMT3A或ASXL1的剪接体基因突变和共突变模式对髓系肿瘤的阳性预测值为0.86至1.0。
  • 诊断不明确者携带1个或以上体细胞突变与随访期间发生髓系肿瘤的高概率相关(风险比=13.9,P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Unexplained blood cytopenias, in particular anemia, are often found in older persons. The relationship between these cytopenias and myeloid neoplasms like myelodysplastic syndromes is currently poorly defined. We studied a prospective cohort of patients with unexplained cytopenia with the aim to estimate the predictive value of somatic mutations for identifying subjects with, or at risk of, developing a myeloid neoplasm. The study included a learning cohort of 683 consecutive patients investigated for unexplained cytopenia, and a validation cohort of 190 patients referred for suspected myeloid neoplasm. Using granulocyte DNA, we looked for somatic mutations in 40 genes that are recurrently mutated in myeloid malignancies. Overall, 435/683 patients carried a somatic mutation in at least 1 of these genes. Carrying a somatic mutation with a variant allele frequency ≥0.10, or carrying 2 or more mutations, had a positive predictive value for diagnosis of myeloid neoplasm equal to 0.86 and 0.88, respectively. Spliceosome gene mutations and comutation patterns involving TET2, DNMT3A, or ASXL1 had positive predictive values for myeloid neoplasm ranging from 0.86 to 1.0. Within subjects with inconclusive diagnostic findings, carrying 1 or more somatic mutations was associated with a high probability of developing a myeloid neoplasm during follow-up (hazard ratio = 13.9, P < .001). The predictive values of mutation analysis were confirmed in the independent validation cohort. The findings of this study indicate that mutation analysis on peripheral blood granulocytes may significantly improve the current diagnostic approach to unexplained cytopenia and more generally the diagnostic accuracy of myeloid neoplasms.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Malcovati L, Gallì A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017. PMID: 28424163. doi:10.1182/blood-2017-01-763425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。